Karin Havenith

1.2k citations

40 papers · 829 indexed · 1 hit paper · h-index 12

Impact in

Oncology top 5%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
Pathology and Forensic Medicine top 5%
- Lymphoma Diagnosis and Treatment

Papers in ⓘ

Oncology 35
- CAR-T cell therapy research 23
- HER2/EGFR in Cancer Research 11
Pathology and Forensic Medicine 12
- Lymphoma Diagnosis and Treatment 11

Co-authors: Jay Feingold (8 shared papers)Mehdi Hamadani (11 shared papers)Paolo F. Caimi (10 shared papers)John Radford (4 shared papers)Melhem Solh (4 shared papers)David Ungar (4 shared papers)Brad S. Kahl (4 shared papers)Carmelo Carlo‐Stella (9 shared papers)
Journals: Cancer Research (12 papers)Blood (8 papers)Hematological Oncology (3 papers)Molecular Cancer Therapeutics (1 paper)Clinical Cancer Research (1 paper)
Partner nations: United States United Kingdom Italy

In The Last Decade

Karin Havenith

37 papers receiving 818 citations

Hit Papers

align trajectories log scale

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial 2021 · 264 citations

Peers

Countries citing papers authored by Karin Havenith

Since Specialization

Citations

This map shows the geographic impact of Karin Havenith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Havenith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Havenith more than expected).

Fields of papers citing papers by Karin Havenith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Havenith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Havenith. The network helps show where Karin Havenith may publish in the future.

Co-authors

The 25 scholars most cited alongside Karin Havenith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Karin Havenith Line = papers co-authored together Karin Havenith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial The Lancet Oncology ·Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit M. Ardeshna, Mehdi Hamadani, Brian Hess, Brad S. Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Karin Havenith, Jay Feingold, Shui He, Yajuan Qin, David Ungar, Xiaoyan Zhang, Carmelo Carlo‐Stella Hit paper breakdown →	2021	264
2	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma Blood ·Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl	2020	122
3	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Clinical Cancer Research ·Brad S. Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Jay Feingold, Kirit M. Ardeshna, Melhem Solh, Leonard T. Heffner, David Ungar, Shui He, Joseph Boni, Karin Havenith, Owen A. O’Connor	2019	77
4	Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study The Lancet Haematology ·Mehdi Hamadani, Graham P. Collins, Paolo F. Caimi, Felipe Samaniego, Alexander I. Spira, Andrew Davies, John Radford, Tobias Menne, Anand B. Karnad, Jasmine Zain, Paul Fields, Karin Havenith, Hans G. Cruz, Shui He, Joseph Boni, Jay Feingold, Jens Wuerthner, Steven M. Horwitz	2021	63
5	CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity Journal for ImmunoTherapy of Cancer ·Francesca Zammarchi, Karin Havenith, François Bertelli, Balakumar Vijayakrishnan, Simon Chivers, Patrick H. van Berkel	2020	55
6	Features of Macrophage Differentiation Induced by p19INK4d, a Specific Inhibitor of Cyclin D–Dependent Kinases Blood ·Masashi Adachi, Martine F. Roussel, Karin Havenith, Charles J. Sherr	1997	44
7	Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia Blood Advances ·Nitin Jain, Wendy Stock, Amer M. Zeidan, Ehab Atallah, James McCloskey, Leonard T. Heffner, Benjamin Tomlinson, Bhavana Bhatnagar, Jay Feingold, David Ungar, Grace Chao, Xiaoyan Zhang, Yajuan Qin, Karin Havenith, Hagop M. Kantarjian, Matthew J. Wieduwilt	2020	36
8	Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study Leukemia Research ·Aaron D. Goldberg, Ehab Atallah, David A. Rizzieri, Roland B. Walter, Ki-Young Chung, Alexander I. Spira, Wendy Stock, Martin S. Tallman, Hans G. Cruz, Joseph Boni, Karin Havenith, Grace Chao, Jay Feingold, Jens Wuerthner, Melhem Solh	2020	27
9	Features of Macrophage Differentiation Induced by p19INK4d, a Specific Inhibitor of Cyclin D–Dependent Kinases Blood ·Masashi Adachi, Martine F. Roussel, Karin Havenith, Charles J. Sherr	1997	18
10	ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers European Journal of Cancer ·Francesca Zammarchi, Simon Chivers, David G. Williams, Lauren Adams, Maria Mellinas‐Gomez, Peter Tyrer, Simon Corbett, François D’Hooge, Sandamali Dissanayake, Simone Sims, Karin Havenith, Philip W. Howard, J.A. Hartley, Patrick H. van Berkel	2016	14
11	hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies. Blood ·Francesca Zammarchi, Simon Corbett, Lauren Adams, Maria Mellinas‐Gomez, Peter Tyrer, Sandamali Dissanayake, Simone Sims, Karin Havenith, Simon Chivers, David G Willimas, Philip W. Howard, John A. Hartley, Patrick van Berkel	2016	12
12	A Subset of Splenic Macrophages Process and Present Native Antigen to Naive Antigen-Specific CD4+T-Cells from Mice Transgenic for an αβ T-Cell Receptor Cellular Immunology ·David S. Askew, Janet Gatewood, Eliva Olivas, Karin Havenith, W. S. G. Walker	1995	11
13	INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT‐301, A NOVEL PYRROLOBENZODIAZAPINE‐BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON‐HODGKIN LYMPHOMA Hematological Oncology ·Steven M. Horwitz, Michelle A. Fanale, A. Spira, Karin Havenith, Shui He, Jay Feingold, Mehdi Hamadani	2017	8
14	Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies Blood ·Francesca Zammarchi, David G. Williams, Lauren Adams, Karin Havenith, Simon Chivers, François D’Hooge, Philip W. Howard, John A. Hartley, Patrick H. van Berkel	2015	8
15	ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies Molecular Cancer Therapeutics ·Francesca Zammarchi, Karin Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, François Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A. Hartley, Patrick H. van Berkel	2024	6
16	Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant Molecular Therapy ·Jenny Yeung, Aiyin Liao, Matthew Shaw, Soraia Silva, Winston Vetharoy, Diego León Rico, Ian Kirby, Francesca Zammarchi, Karin Havenith, Lolke de Haan, Patrick H. van Berkel, Neil J. Sebire, Olumide Ogunbiyi, Claire Booth, H Bobby Gaspar, Adrian J. Thrasher, Kerry Chester, Persis Amrolia	2024	6
17	FIRST CLINICAL RESULTS OF ADCT‐402, A NOVEL PYRROLOBENZODIAZEPINE‐BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B‐CELL LINEAGE NHL Hematological Oncology ·Brad S. Kahl, Mehdi Hamadani, Paolo F. Caimi, Erin Reid, Karin Havenith, Shasha He, Jay Feingold, Olya O’Connor	2017	6
18	CLINICAL ACTIVITY OF LONCASTUXIMAB TESIRINE PLUS IBRUTINIB IN NON‐HODGKIN LYMPHOMA: UPDATED LOTIS 3 PHASE 1 RESULTS Hematological Oncology ·Julien Depaus, Nina Wagner‐Johnston, Pier Luigi Zinzani, Tycel Phillips, J Malý, Silvia Ferrari, Emmanuel Bachy, Locke J. Bryan, Vincent Delwail, Murali Janakiram, Sophie de Guibert, Monica Tani, Vivian Dai, Karin Havenith, Joseph Boni, X L He, A. Ervin-Haynes, Carmelo Carlo‐Stella	2021	5
19	Abstract 637: Preclinical activity of hLL2-PBD, a novel anti-CD22 antibody-pyrrolobenzodiazepine (PBD) conjugate in models of non-Hodgkin lymphoma Cancer Research ·Francesca Zammarchi, David G. Williams, Karin Havenith, François D’Hooge, Philip W. Howard, John A. Hartley, Patrick van Berkel	2015	5
20	CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling Blood ·Paolo F. Caimi, Mehdi Hamadani, Carmelo Carlo‐Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Serafino Pantano, Karin Havenith, Ying Wang, Joseph Boni	2022	4

About Karin Havenith

Karin Havenith is a scholar working on Oncology, Pathology and Forensic Medicine, Genetics, Radiology, Nuclear Medicine and Imaging and Immunology, having authored 40 papers that have together received 829 indexed citations. Recurring topics across this work include CAR-T cell therapy research (23 papers), HER2/EGFR in Cancer Research (11 papers), Lymphoma Diagnosis and Treatment (11 papers), Cancer therapeutics and mechanisms (8 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Synthesis and pharmacology of benzodiazepine derivatives (6 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Oncology (679 citations), Pathology and Forensic Medicine (408 citations), Genetics (123 citations), Radiology, Nuclear Medicine and Imaging (207 citations) and Immunology (173 citations). Karin Havenith has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Jay Feingold, Mehdi Hamadani, Paolo F. Caimi, John Radford, Melhem Solh, David Ungar, Brad S. Kahl, Carmelo Carlo‐Stella, Kirit M. Ardeshna and Yajuan Qin. Their work appears in journals such as Cancer Research, Blood, Hematological Oncology, Molecular Cancer Therapeutics and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact